Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (PLWH). We analyzed...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS research and therapy 2021-09, Vol.18 (1), p.58-58, Article 58
Hauptverfasser: Wolf, Eva, Boesecke, Christoph, Balogh, Annamaria, Bidner, Helen, Cordes, Christiane, Heiken, Hans, Krznaric, Ivanka, Kümmerle, Tim, Stellbrink, Hans-Jürgen, Schneider, Jochen, Spinner, Christoph D
Format: Artikel
Sprache:eng
Schlagworte:
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
CD4 antigen
Darunavir
Darunavir - therapeutic use
Demographic aspects
Dolutegravir
Dosage and administration
Drug development
Drug Resistance
Drug therapy
Female
Heterocyclic Compounds, 3-Ring
HIV
HIV drug resistance
HIV Infections - drug therapy
HIV patients
HIV-1 - genetics
Human immunodeficiency virus
Humans
Integrase
Integrase inhibitors
Lymphocytes T
Male
Middle Aged
Mutation
Nucleotides
Oxazines
Patients
Piperazines
Protease inhibitors
Proteinase inhibitors
Pyridones
Response rates
Ribonucleic acid
Risk factors
RNA
Short Report
Switching
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (PLWH). We analyzed virologic outcomes with respect to treatment history and HIV drug resistance. Post hoc analysis of a randomized trial. Main inclusion criteria were an HIV RNA level
ISSN:1742-6405
1742-6405
DOI:10.1186/s12981-021-00384-6